Anatomic Biomarkers of Macular Edema Associated with Retinal Vein Occlusion.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
12 2022
Historique:
received: 17 03 2022
revised: 21 06 2022
accepted: 22 06 2022
pubmed: 6 7 2022
medline: 7 12 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

To assess the relationship between best-corrected visual acuity (BCVA) and anatomic features in patients with macular edema (ME) related to retinal vein occlusion (RVO). Post hoc analysis of 3 clinical trials, which included verified diagnoses, protocol refractions, and the assessment of OCT and fluorescein angiography (FA) images at a masked reading center. Patients diagnosed with RVO-ME. Correlation analyses were performed to determine the correlation between BCVA and macular anatomy at baseline and at 12 and 24 weeks and between changes from baseline to 12 and 24 weeks. The correlations between BCVA and central subfield thickness (CST), ellipsoid zone (EZ) integrity, intraretinal fluid (IRF), subretinal fluid, central leakage, and ischemia were assessed. In a total of 828 eyes with RVO-ME, the mean age, BCVA, and CST at baseline was 64.7 years, 51.1 letters, and 656.9 μm, respectively. At baseline, a moderate negative correlation was observed between BCVA and CST (r = - 0.56, P < 0.001). At weeks 12 and 24, the mean BCVA of eyes with definitely abnormal (absent) EZ was statistically significantly worse than that of eyes with normal EZ. At week 12, a moderate negative correlation was observed between changes in BCVA and changes in CST (r = - 0.35, P < 0.001), with a similar degree of association noted at week 24 (r = - 0.35, P < 0.001). At weeks 12 and 24, eyes that showed any improvement in central IRF showed a greater improvement in BCVA than eyes that showed no improvement worsening (week 12: 463 eyes, 18.3 letters vs. 177 eyes, 13.0 letters, respectively, P < 0.001) and (week 24: 332 eyes, 20.2 letters vs. 131 eyes, 13.3 letters, respectively, P < 0.001). With respect to the correlation between baseline BCVA and fluorescein leakage or capillary nonperfusion, the Pearson correlation coefficients were - 0.41 (P < 0.001) and - 0.16 (P = 0.060), respectively. In addition to CST, there are important clinically relevant relationships between BCVA and both OCT and FA anatomic features in patients with RVO-ME.

Identifiants

pubmed: 35781069
pii: S2468-6530(22)00324-4
doi: 10.1016/j.oret.2022.06.016
pmc: PMC9927025
mid: NIHMS1871173
pii:
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Vascular Endothelial Growth Factor A 0
Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1206-1220

Subventions

Organisme : NEI NIH HHS
ID : R01 EY030851
Pays : United States

Informations de copyright

Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Références

Ophthalmology. 2007 Mar;114(3):525-36
pubmed: 17123615
Arch Ophthalmol. 2009 Sep;127(9):1115-28
pubmed: 19752420
Retina. 2016 Jun;36(6):1170-6
pubmed: 26655606
Ophthalmol Retina. 2018 Apr;2(4):320-328
pubmed: 31047241
Eye Vis (Lond). 2018 Oct 11;5:27
pubmed: 30386806
Am J Ophthalmol. 2022 May;237:310-324
pubmed: 34740628
Ophthalmol Retina. 2020 Jan;4(1):67-76
pubmed: 31669329
Am J Ophthalmol. 2017 Aug;180:8-17
pubmed: 28549848
Biomed Res Int. 2015;2015:853728
pubmed: 26167505
Am J Ophthalmol. 2011 Dec;152(6):1044-1052.e5
pubmed: 21861971
Am J Ophthalmol. 2017 Oct;182:160-167
pubmed: 28837790
Ophthalmology. 2009 Mar;116(3):504-12
pubmed: 19167078
Ophthalmol Retina. 2019 Dec;3(12):1056-1066
pubmed: 31473172
Am J Ophthalmol. 2017 May;177:116-125
pubmed: 28237411
Ophthalmol Retina. 2021 Jul;5(7):633-647
pubmed: 33130256
Ophthalmol Retina. 2018 Aug;2(8):836-841
pubmed: 30221215
JAMA Ophthalmol. 2019 Sep 01;137(9):977-985
pubmed: 31246237

Auteurs

Thomas A Ciulla (TA)

Clearside Biomedical, Alpharetta, Georgia. Electronic address: thomasciulla@gmail.com.

Barry Kapik (B)

Clearside Biomedical, Alpharetta, Georgia.

Allen Hu (A)

Cumberland Valley Retina Consultants, Hagerstown, Maryland.

Alon Harris (A)

Icahn School of Medicine at Mount Sinai, New York City, New York.

Michael S Ip (MS)

Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Barbara Blodi (B)

Department of Ophthalmology, University of Wisconsin, Wisconsin, Madison.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH